BlackRock Reports 6.8% Passive Stake In Wave Life Sciences, A Stock Down About 81% This Year
BlackRock holds 13,356,138 Wave shares as of September 30, while Wave posted a $61.9 million third-quarter net loss.
BlackRock holds 13,356,138 shares of Wave Life Sciences, or 6.8% of the common stock, according to a passive ownership filing (a Schedule 13G) made Tuesday. Wave, a clinical-stage biotech that develops RNA medicines, closed at $3.45 on Tuesday, with a market value of $633 million.
How BlackRock holds the shares
The position is as of September 30. BlackRock reports sole voting power over 13,040,746 shares and shared voting power over none, and files as a parent holding company.
The holding covers certain BlackRock business units, and an exhibit lists the subsidiaries involved, among them BlackRock Fund Advisors and BlackRock Institutional Trust Company. BlackRock certified that the shares were acquired and are held in the ordinary course of business, not to change or influence control of Wave.
The percentage follows the SEC's Rule 13d-3 method, which counts warrants, options and convertibles exercisable within 60 days in both the holding and the share base.
A stock down about 81% this year
Wave reported third-quarter results the same day. Its net loss was $61.9 million. Cash and marketable securities stood at $431.0 million, and the company expects that to fund operations into the third quarter of 2028, according to its results release.
Zacks noted that the shares are down about 81.1% since the start of the year, against a 12.1% gain for the S&P 500.
Wave builds its drugs on its PRISM platform. Its lead programs target obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and a genetic form of liver disease (WVE-008), and it also has Duchenne muscular dystrophy and Huntington's disease programs.
Fourth-quarter milestones
Wave expects a $12 million milestone payment from GSK in the fourth quarter. It also expects 600 mg data from the early-stage portion of its INLIGHT obesity study in the same period.
Both the GSK payment and the 600 mg obesity data are slated for the fourth quarter.
Sources
- SCHEDULE 13G — BlackRock, Inc. re: Wave Life Sciences, Inc. (WVE) — SEC EDGAR
- SCHEDULE 13G Exhibit 99 — SEC EDGAR
- Wave Life Sciences GAAP EPS of -$0.30 beats by $0.03, revenue of $13.16M beats by $8.77M (WVE:NASDAQ) | Seeking Alpha — seekingalpha.com
- Wave Life Sciences (WVE) Reports Q3 Loss, Tops Revenue Estimates — Yahoo Finance
- Wave Life Sciences: Q3 Earnings Snapshot – WTOP News — wtop.com
- WAVE Life Sciences Q3 Earnings Call Highlights — Yahoo Finance
- Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update — Yahoo Finance